Featured on: Gerson Lehrman Group
Publication date: Jul 27, 2009
Publication date: Jul 27, 2009
A new drug under development has shown excellent results in a Phase I trial for melanoma. The drug, PLX-4032, has been developed by the company Plexxikon in partnership with Roche. It is hoped that the drug will progress rapidly through Phase II and Phase III testing, followed by accelerated FDA approval.
Read Full Article
Read Full Article
More Skin Articles
Pediatric Dermatitis: Efalizumab Succeeds Where Standard Treatments FailEczema Patients Most At Risk For Dangerous Viral Infections
12 Ways To Protect Your Skin And Prevent Skin Cancer
Psoriasis-like Inflammation: Crucial Role For The Protein CCR6
'No Doubt' Sunbeds Cause Cancer
A Centuries-Old Remedy For Problem Skin & Hair
UCSD Pits Herpes Against Melanoma
Is Your Skin Stressed Out?
Campus Researchers Find Link To Healing Process
Pediatric Psoriasis: C-reactive Protein Levels Assocaited With Disease Severity, BMI
